IB Statin-AC 20 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), designed for the management of cardiovascular diseases. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) levels, contributing to the prevention of atherosclerosis and subsequent cardiovascular events. Clopidogrel, another antiplatelet agent, inhibits the P2Y12 component of ADP receptors on platelet surfaces, further reducing platelet activation and aggregation. This combination is primarily indicated for patients at high risk of myocardial infarction, stroke, or other thrombotic complications, particularly those with established coronary artery disease or peripheral arterial disease. The synergistic effects of these agents provide comprehensive cardiovascular protection by addressing lipid abnormalities and platelet-mediated thrombosis. IB Statin-AC 20 should be used under medical supervision with regular monitoring of liver function, lipid profile, and bleeding parameters. Caution is advised in patients with bleeding disorders, hepatic impairment, or hypersensitivity to any component. Adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes and reduces cardiovascular morbidity and mortality.